Neurocrine Takes Delivery of Genedata’s Gene Expression Analysis System
News Dec 08, 2005
Genedata has announced that biopharmaceutical company Neurocrine Biosciences has licensed the gene expression analysis system Genedata Expressionist® for biomarker discovery and in-silico prediction and integrated it with Neurocrine’s research informatics infrastructure.
Scientists at Neurocrine will use Expressionist in its pre-clinical discovery program, which focuses on neurological and endocrine-related diseases and disorders.
"Genedata’s software deployment plan extends to on-site training in the system’s powerful high throughput functionalities," explained Bill Wilson, Head of IT at Neurocrine.
"Scientists at Neurocrine have already used Expressionist to process and evaluate over 1500 GeneChips®, thus preparing the data for detailed expression analysis."
High throughput data processing is achieved using Expressionist’s GCOS Monitor, a production mode processing and database tool that is closely integrated with Affymetrix GCOS (GeneChip® Operating Software).
"We are pleased to support Neurocrine in their research efforts," says Matthew Trunnell, Managing Director USA, Genedata Inc.
Expressionist has been developed for high throughput applications and offers standardized, automated workflows for processing, analyzing and managing experimental transcriptomics, proteomics and metabolomics data.
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE